Previous 10 |
ROCKVILLE, Md., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Rexahn has engaged Oppenheimer & Co., Inc. as its financial advis...
Gainers: Cambrex Corporation (NYSE: CBM ) +47% . Weight Watchers International (NASDAQ: WW ) +40% . Paratek Pharmaceuticals (NASDAQ: PRTK ) +35% . Owens & Minor (NYSE: OMI ) +29% . Match Group (NASDAQ: MTCH ) +27% . SolarEdge Technologies (NASDAQ: SEDG ) +24% . Guardant Hea...
Rexahn Pharmaceuticals (NYSEMKT: REXN ): Q2 GAAP EPS of -$0.61 beats by $0.34 . Cash and equivalents of $16.3M. Press Release More news on: Rexahn Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
ROCKVILLE, Md., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced financial results for the three and...
News, Short Squeeze, Breakout and More Instantly...
Rexahn Pharmaceuticals Company Name:
REXN Stock Symbol:
NYSE Market:
FARMINGTON HILLS, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that will participate in the H.C. Wainwrigh...
Merger completed with Rexahn Pharmace u ticals c reat ing a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates Trading under "OCUP" on the Nasdaq Capital Market to begin No...
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly after 4:00 pm (EST) today, Thursday, November 5, 202...